The eight new ACIP members met for the first time June 25 after Kennedy fired all 17 original members of the committee June 9 ...

A new national guideline provides evidence-based recommendations for diagnosing, treating, and preventing pediatric ...

The United States could soon have another tool in the fight against respiratory syncytial virus, an illness that’s the No. 1 ...

Merck & Co., Inc. (NYSE:MRK) is one of the 10 Best Value Stocks to Buy According to Billionaires. The company announced that ...

A group of outside advisers to the US Centers for Disease Control and Prevention voted 5-2 to recommend use of a new shot ...

The votes in favor of Merck’s shot are a sigh of relief after Kennedy gutted the panel and tapped replacements, some of whom ...

Robert F. Kennedy Jr. had fired all 17 members of a key vaccine panel. Now his new panel recommended a new infant RSV vaccine ...

Merck & Co., Inc. (NYSE:MRK) is one of the 11 Best 52-Week Low Stocks to Buy Right Now. On June 26, Merck & Co., Inc.

MPV tends to hit hardest in young children, older adults and people with weakened immune systems. A virologist explains.

U.S. FDA Approves Merck’s ENFLONSIA™ (clesrovimab-cfor) for Prevention of Respiratory Syncytial Virus (RSV) Lower Respiratory Tract Disease in Infants Born During or Entering Their First RSV ...

The CDC's vaccine advisory committee voted on Thursday to recommend infants receive a newer monoclonal antibody shot for ...

Merck's Enflonsia vaccine for respiratory syncytial virus won approval from the Centers for Disease Control and Prevention's ...